US/UK/Canada

Share

Contacts

  • Göran Beijer

    • Links

    Pick a time period -
    Tags ( Active)

    Good safety and improved erectile function reported from Dicot’s phase 1 study

    Press release: Uppsala, April 23, 2024.  Dicot's completed phase 1 clinical study demonstrates that the company's drug candidate LIB-01 has a very good safety profile, which was the primary objective of the study. In addition to this, the company can deduce an efficacy signal from the study where participants reported an improved erectile function, in some cases beyond 28 days post first dose.The primary objective of Dicot's phase 1 study has been to investigate the safety profile in humans for LIB-01, the company’s drug candidate for treatment of erectile dysfunction. In January, Dicot

    Dicot in preparation for clinical phase 2a trial

    Press release: Uppsala, Sweden, April 12, 2024. The pharmaceutical company Dicot, which recently announced that a reporting from the last part of the phase 1 study will be published at the end of April, is in parallel preparing for a clinical phase 2a trial with its potency drug candidate. Today, the company can announce that a partner has been contracted to conduct the trial and that the study drug has been produced by Thermo Fisher Scientific, the contracted manufacturer.Dicot will soon report the results from the last part in the clinical phase 1 study. In parallel, preparatory

    Reporting from Dicot's phase 1 study end of April

    Press release: Uppsala, April 5, 2024. Yesterday, Dicot completed the clinical phase of the second and final part of its phase 1 study. The company can thus confirm that the reporting from this part of the study will be published at the end of April, followed by an in-depth summary of results for the entire phase 1 study later in the second quarter.Dicot's Phase 1 study of the potency drug candidate LIB-01 is placebo-controlled and double-blind with the primary objective to investigate the safety profile in humans. It started in August last year and consists of two parts: single doses (SAD)

    BioStock: Dicot’s phase I study fully recruited

    Dicot continues to stay on schedule in its clinical phase I study. In January, the company, which is developing the next generation of potency drugs, was able to make a first positive data reading from the study, and now the last participant in the trial has been recruited.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/dicots-phase-i-study-fully-recruited/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    Recruitment completed in Dicot’s phase 1 trial

    Press release: Uppsala, Sweden, March 11, 2024. Today, the potency drug developer Dicot announces that the recruitment to the final part of its phase 1 study is completed. The study is thus proceeding according to the previously communicated timeline and the results are expected to be announced during the second quarter.Dicot's phase 1 study, aiming at investigating the safety profile in humans, started in August 2023 and consists of two parts: SAD (single dose) and MAD (multiple doses). The study is placebo-controlled and double-blind, meaning that some participants receive LIB-01 and some

    Dicot’s CEO tells BioStock: “Several prominent people want to be part of the journey”

    Uppsala-based Dicot recently released its year-end report. CEO Elin Trampe notes that there is great confidence in the company’s research, both among investors and researchers in the field. BioStock contacted her in connection with the report to get a comment on the latest news and to find out more about what’s on this spring’s to-do list.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/dicots-ceo-several-prominent-people-want-to-be-part-of-the-journey/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

    Dicot AB Year-End Report 2023

    Press release: Uppsala, Sweden, February 26, 2024. Dicot AB (publ) publishes its year-end report for the financial year 2023 and for the fourth quarter. The year-end report is available as an attached document and on the company's website www.dicot.se.Fourth quarter, October-December 2023 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -15,661 (-8,604) · Earnings per share amounts to SEK -0.02 (-0.06) Financial year January-December 2023 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -44,157 (-31,

    BioStock: Good safety profile for Dicot’s LIB-01

    For Uppsala-based Dicot, the phase I study with the potency drug candidate LIB-01 is currently underway to investigate the safety profile in humans. The company recently completed the first part of the study and reports that it has not seen any serious side effects, and that the safety profile appears to be very good. BioStock reached out to CEO Elin Trampe to find out more.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/good-safety-profile-for-dicots-lib-01/ This is a press release from BioStock - Connecting Innovation & Capital.

    Positive results from the first part of Dicot's phase 1 study

    Press release: Uppsala, Sweden, January 23, 2024. Dicot presents positive results from the first part of its phase 1 clinical study showing that LIB-01 has a very good safety profile. There were no serious adverse effects. The results also show that the drug is well absorbed in the body, which puts the company in a strong position for clinical phase 2.The primary objective of Dicot's phase 1 study is to investigate the safety of the potency drug candidate LIB-01 in humans. The study is double-blind and placebo-controlled and consists of two parts: SAD and MAD. The SAD part studies

    Dicot applies for patent covering new manufacturing technology

    Press release: Uppsala, Sweden, January 11, 2024. The pharmaceutical company Dicot has applied for a patent covering a novel technology to manufacture the starting material for its potency drug candidate. It concerns a custom-designed approach in cell cultivation developed in partnership with Uppsala University.In 2022, Dicot started a research project with Uppsala University and W. Szafer Institute of Botany to investigate whether the starting material for the drug candidate LIB-01 could be produced by using plant cells grown in cultures; an established technology for large-scale

    Dicot invited to present at ESSM for the third time

    Press release: Uppsala, Sweden, January 5, 2024. The pharmaceutical company Dicot's preclinical research results have been selected to be presented at the European Society for Sexual Medicine's conference in February. It is the third year in a row that Dicot will present at Europe's largest event in the field of sexual medicine.The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine whose annual conference brings together prominent researchers and doctors from all over the world. The ESSM Scientific Council has selected Dicot's

    BioStock: Interim results from Dicot’s phase I study to be released earlier than expected

    Dicot’s phase I study is progressing well and the first results are now expected to be presented as early as the beginning of next year. This is earlier than the company first estimated. BioStock reached out to CEO Elin Trampe to find out what this means for the project and what she sees ahead of her when it’s time to put 2023 behind her.Read the full article at biostock.se : https://www.biostock.se/en/2023/12/interim-results-from-dicots-phase-i-study-to-be-released-earlier-than-expected/ This is a press release from BioStock - Connecting Innovation &

    Partial results from Dicot's phase 1 trial to be presented early next year

    Press Release: Uppsala, December 15, 2023. Yesterday, the potency drug developer Dicot concluded the clinical part of the SAD, earlier than initially planned. Consequently, the company will be able to report these results already in the January-to-February transition. Results from the second and final part of the phase 1 trial are expected to be communicated in the second quarter of next year, as previously announced.Dicot's phase 1 trial of the potency drug candidate LIB-01 is placebo-controlled and double-blinded, with the primary objective of investigating the safety profile in humans.

    BioStock: Great interest in Dicot’s LIB-01

    Many interested parties are keeping an eye on the development of LIB-01, Dicot's drug candidate for the treatment of erectile dysfunction, and the interest only seem to increase. At least if you ask the company's CEO, Elin Trampe, who BioStock talked to in connection with the Sexual Medicine Society of North America's annual conference.Read the full article at biostock.se : https://www.biostock.se/en/2023/11/great-interest-in-dicots-lib-01/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    Dicot gains significant interest at North America's major sexual medicine congress

    Press release: Uppsala, November 24, 2023. During the fall, the pharmaceutical company Dicot received acceptance for an abstract presentation at North America's largest congress in sexual medicine, recently held in San Diego. Dicot's CSO, Charlotta Gauffin, participated alongside Professor François Giuliano, who presented the company's preclinical research findings, and sexual medicine expert Dr. Harin Padma-Nathan.The annual congress of Sexual Medicine Society of North America is the premier gathering for physicians, researchers, and industry professionals in sexual medicine in North

    Dicot's  warrants of series TO5 subscribed at 85.4%, provides the company 16.5 MSEK before cost

    Press release: Uppsala, Sweden, November 17, 2023. Dicot AB (publ) today announces that the exercise of warrants series TO5 was approximately 85.4 percent of the outstanding number. Through the exercise of 192,414,488 warrants, 192,414,488 shares were subscribed for at a subscription price of SEK 0.086 per share. Dicot is thus provided with approximately 16.5 MSEK before issue costs. No subscription guarantees had been procured prior to the exercise."I would like to say a big thank you to everyone who subscribed and therby showed their confidence in Dicot and the exiting time we have ahead

    Dicot initiates repeated dosing in its clinical study

    Press release: Uppsala, November 14, 2023. The potency drug developer Dicot's phase 1 study is now entering its second and final part. After the previously announced start of recruitment of participants to what is called MAD, the dosing itself is now ready to start, where the participants will receive multiple doses.Tomorrow morning, the first participants in Dicot's second and final part of its phase 1 clinical trial will be dosed. Initially, participants were given a single dose (called Single Ascending Dose, SAD). Now new participants will receive repeated dosing (Multiple Ascending Dose,

    Letters of intent from major owners, directors, and management to subscribe for SEK 4.7 million (24.2%) in Dicot's TO5 which runs until November 15, 2023

    Press release: Uppsala, Sweden, November 2, 2023. Major shareholders in Dicot and all members of the board of directors and management holding warrants of series TO5 have in dialog with Dicot announced their intention to exercise those. This corresponds to a total investment of approximately SEK 4.7 million, or approximately 24.2 percent of total outstanding warrants in TO5. The subscription period for TO5 runs until November 15, 2023."It is very gratifying that we once again see strong support from our largest owners, board and management. This confidence means a lot to us now that the

    The exercise period for warrants TO5 in Dicot starts today

    Press release: Uppsala, Sweden, November 1, 2023.  Today, November 1, 2023, the exercise period for warrants of series TO5 in Dicot AB (publ), which were included in the unit issue in January 2023, begins. Subscription period lasts until November 15, 2023.Each warrant of series TO5 entitles the holder to subscribe to one new share during the period November 1-15, 2023, to the exercise price of SEK 0.086. If all warrants are exercised, Dicot will receive approximately SEK 19.4 million before issuing costs. The issue in January with its options TO4 in June and TO5 in November are all

    Dicot AB presents Interim report Q3 2023

    Press release: Uppsala, Sweden, October 31, 2023. Dicot AB (publ) publishes the interim report for the period January-September 2023. The report is available as an attached document and on the company's website www.dicot.se. Below is a summary of the report.Third quarter, June-September 2023 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -8,501 (-5,073) · Earnings per share amounts to SEK -0.01 (-0.04) ”Important events are taking place for Dicot. At a research clinic in Uppsala, exactly 24 individuals have already been dosed”, says Elin

    The exercise price for warrants TO5 in Dicot has been set to SEK 0.086. The subscription period starts on November 1, 2023

    Press release: Uppsala, Sweden, October 30, 2023. Dicot AB (publ) completed a rights issue of units during January 2023 which was oversubscribed to 110%. One unit consisted of four newly issued shares, three warrants of series TO4 and three warrants of series TO5. Each warrant TO5 entitles the holder to subscribe for one new share during the period November 1 - 15, 2023, with payment in cash and shall correspond to 70 % of the volume-weighted average price of Dicot's share during the period October 13 - 27, 2023. During the measurement period, the volume-weighted average price in Dicot’s

    The Nomination committee for Dicot AB appointed

    Press release: Uppsala, October 26, 2023. According to decision at the Annual General Meeting of Dicot AB on May 23, 2023, the Nomination committee for the Annual General Meeting on May 6, 2024, shall consist of three members representing the three largest shareholders as of the end of September 2023.Based on the above, the Nomination committee for the 2024 Annual General Meeting (AGM) has been appointed with the following three members: · Bertil Lindkvist · Tore Robertsson · Torsten Söderberg The chairman of the board Eva Sjökvist Saers is convening the Nomination committee.

    BioStock: Dicot initiates repeated dosing in phase I study

    Dicot recently entered phase I with its drug candidate LIB-01, where the first step is to test single dosing on healthy volunteers. In parallel, the company is now starting the second part of the study, testing repeated dosing of the candidate. The first results from the study are expected in the spring.Read the full article at biostock.se : https://www.biostock.se/en/2023/10/dicot-initiates-repeated-dosing-in-phase-i-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe